The Federal Trade Commission has extended its antitrust review of Barr pharmaceuticals Inc.'s proposed tender offer to acquire Pliva D.D ., a Croatian generic drug maker, Barr said Tuesday.
United States Federal Trade Commission extends antitrust review of Barr's proposed Pliva buy.